S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:LNSR

LENSAR (LNSR) Stock Price, News & Analysis

$3.06
+0.04 (+1.32%)
(As of 04/17/2024 ET)
Today's Range
$3.00
$3.25
50-Day Range
$3.02
$5.00
52-Week Range
$1.80
$5.30
Volume
5,690 shs
Average Volume
41,182 shs
Market Capitalization
$34.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

LENSAR MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
161.4% Upside
$8.00 Price Target
Short Interest
Healthy
0.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.43 out of 5 stars

Medical Sector

711th out of 913 stocks

Surgical & Medical Instruments Industry

69th out of 89 stocks

LNSR stock logo

About LENSAR Stock (NASDAQ:LNSR)

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LNSR Stock Price History

LNSR Stock News Headlines

Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Analysts’ Top Healthcare Picks: 89bio (ETNB), UnitedHealth (UNH)
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
LENSAR Q4 2023 Earnings Preview
Navigating 6 Analyst Ratings For Viridian Therapeutics
LENSAR Stock (NASDAQ:LNSR), Short Interest Report
LENSAR Decline Means Insider Profits Down To US$42k
LENSAR's Earnings Outlook
Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
See More Headlines
Receive LNSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
4/17/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LNSR
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+161.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,380,000.00
Pretax Margin
-34.11%

Debt

Sales & Book Value

Annual Sales
$42.16 million
Book Value
$2.97 per share

Miscellaneous

Free Float
3,874,000
Market Cap
$34.87 million
Optionable
Optionable
Beta
0.47
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

LNSR Stock Analysis - Frequently Asked Questions

Should I buy or sell LENSAR stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LENSAR in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LNSR shares.
View LNSR analyst ratings
or view top-rated stocks.

What is LENSAR's stock price target for 2024?

1 Wall Street research analysts have issued 12-month price objectives for LENSAR's shares. Their LNSR share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 161.4% from the stock's current price.
View analysts price targets for LNSR
or view top-rated stocks among Wall Street analysts.

How have LNSR shares performed in 2024?

LENSAR's stock was trading at $3.51 at the beginning of 2024. Since then, LNSR stock has decreased by 12.8% and is now trading at $3.06.
View the best growth stocks for 2024 here
.

Are investors shorting LENSAR?

LENSAR saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 77,300 shares, an increase of 85.8% from the March 15th total of 41,600 shares. Based on an average daily volume of 43,700 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.8% of the shares of the company are sold short.
View LENSAR's Short Interest
.

When is LENSAR's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LNSR earnings forecast
.

How were LENSAR's earnings last quarter?

LENSAR, Inc. (NASDAQ:LNSR) announced its quarterly earnings data on Monday, March, 4th. The company reported ($0.22) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.22). The company earned $12.11 million during the quarter. LENSAR had a negative trailing twelve-month return on equity of 40.53% and a negative net margin of 34.11%.

How do I buy shares of LENSAR?

Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LNSR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners